使用自动成像平台进行疾病识别和测量，对去势敏感性前列腺癌中PSMA PET治疗反应进行定量评估。
Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement.
作者信息
Duriseti Sai, Berenji Gholam, Tsai Sonny, Rettig Matthew, Nickols Nicholas G
机构信息
VA Greater Los Angeles, Radiation Oncology Service, 11301 Wilshire Blvd, Building 500, Suite 0426, Los Angeles, CA, 90073, USA.
Departments of Radiation Oncology, University of California, Los Angeles, 200 UCLA Medical Plaza, Suite B265, Los Angeles, CA, 90095, USA.
出版信息
Eur J Hybrid Imaging. 2023 Apr 3;7(1):7. doi: 10.1186/s41824-023-00165-6.
RATIONALE
Prostate cancer treatment response may be automatically quantified using a molecular imaging analysis platform targeting prostate-specific membrane antigen (PSMA).
METHODS
A retrospective analysis of patients with castration-sensitive prostate cancer who underwent PSMA-targeted molecular imaging prior to and 3 months or more after treatment was conducted. Disease burden was analyzed with aPROMISE, an artificial intelligence imaging platform that automatically quantifies PSMA-positive lesions. The calculated PSMA scores for prostate/bed, nodal, and osseous disease sites were compared with prostate-specific antigen (PSA) values.
RESULTS
Of 30 eligible patients, the median decline in prostate/bed, nodal, and osseous disease PSMA scores were 100% (range 52-100%), 100% (range - 87-100%), and 100% (range - 21-100%), respectively. PSMA score decline was significantly associated with PSA decline.
CONCLUSION
Changes in aPROMISE PSMA scores are associated with changes in PSA and may quantify treatment response.
原理
可使用靶向前列腺特异性膜抗原（PSMA）的分子成像分析平台自动量化前列腺癌的治疗反应。
方法
对在治疗前及治疗后3个月或更长时间接受PSMA靶向分子成像的去势敏感性前列腺癌患者进行回顾性分析。使用aPROMISE（一种自动量化PSMA阳性病变的人工智能成像平台）分析疾病负担。将计算出的前列腺/瘤床、淋巴结和骨疾病部位的PSMA评分与前列腺特异性抗原（PSA）值进行比较。
结果
在30例符合条件的患者中，前列腺/瘤床、淋巴结和骨疾病PSMA评分的中位数下降分别为100%（范围52%-100%）、100%（范围-87%-100%）和100%（范围-21%-100%）。PSMA评分下降与PSA下降显著相关。
结论
aPROMISE PSMA评分的变化与PSA变化相关，并且可以量化治疗反应。
Zotero 插件